AGC Biologics Partners with AAVantgarde for Gene Therapy Production

AGC Biologics has entered into a significant manufacturing agreement with AAVantgarde to produce two gene therapy candidates aimed at treating inherited eye diseases. This partnership leverages AGC Biologics’ advanced BravoAAV platform and its innovative dual AAV vector approach, which facilitates early and late-phase clinical manufacturing.

The agreement specifically targets the production of two investigational therapies: AAVB-039, designed to address Stargardt disease, and AAVB-081, which focuses on retinitis pigmentosa caused by Usher syndrome type 1B. Both therapies are currently undergoing Phase 1/2 clinical trials in the United States, the United Kingdom, and across Europe. These treatments aim to combat progressive and irreversible vision loss, a condition for which no approved therapies exist.

Advanced Manufacturing Techniques

The manufacturing work will be conducted at AGC Biologics’ Milan Cell and Gene Center of Excellence. This facility supports both early and late-stage clinical supply and boasts a robust history in viral vector manufacturing. The processes will utilize the BravoAAV suspension platform, alongside a dual AAV vector method that addresses the challenges of delivering therapeutic genes that are too large for a single vector. This method allows for the separate packaging of two halves of a gene, which are then reassembled inside the target cell, enabling delivery beyond the typical 4.7-kilobase vector capacity.

AAVantgarde’s Chief Executive, Natalia Misciattelli, expressed enthusiasm about the partnership, stating, “We are delighted to partner with AGC Biologics, a world-class CDMO with deep expertise in viral vector manufacturing.” This collaboration signifies an important step for both companies, enhancing AGC Biologics’ presence in the adeno-associated virus market.

Regulatory Expertise and Future Impact

AGC Biologics has emphasized that this collaboration enables them to apply their extensive experience across various vector types and stages of clinical development. The Milan facility has a commendable track record, having secured ten product approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) over the past 30 years.

The partnership not only underscores AGC Biologics’ commitment to advancing gene therapy production but also highlights the growing demand for innovative treatments targeting rare genetic conditions. As AAVantgarde continues to progress through clinical trials, the outcomes of these therapies could potentially transform the landscape of treatments available for patients suffering from inherited eye diseases.